ts in terms of multiple inflammatory, respiratory and clinical outcomes. Recently, Bristrian proposed the use of parenteral supplementation of fish-oil emulsions, containing substantial amounts of EPA and DHA (4–6 g/d), to treat patients with severe SARS-CoV-2, in order to inhibit cytokine secretion and miti